Mirae Asset Global Investments
CCCC icon

Mirae Asset Global Investments’s C4 Therapeutics CCCC Stock Holding History

Mirae Asset Global Investments’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.1K Sell
4,945
-145
-3% -$496 ﹤0.01% 1470
2026
Q1 		$13.4K Buy
5,090
+381
+8% +$897 ﹤0.01% 1472
2025
Q4 		$8.99K Buy
4,709
+1,958
+71% +$4.64K ﹤0.01% 1606
2025
Q3 		$6.11K Buy
2,751
+8
+0.3% +$19 ﹤0.01% 1603
2025
Q2 		$3.92K Buy
2,743
+368
+15% +$535 ﹤0.01% 1550
2025
Q1 		$4.16K Buy
2,375
+23
+1% +$69 ﹤0.01% 1520
2024
Q4 		$8.91K Buy
+2,352
New +$11.7K ﹤0.01% 1526
2024
Q2 		– Sell
-41,445
Closed -$260K – 1698
2024
Q1 		$260K Buy
+41,445
New +$321K ﹤0.01% 2168
2023
Q2 		– Sell
-17,467
Closed -$54.8K – 2615
2023
Q1 		$54.8K Sell
17,467
-29
-0.2% -$171 ﹤0.01% 2505
2022
Q4 		$103K Buy
17,496
+18
+0.1% +$149 ﹤0.01% 2447
2022
Q3 		$154K Sell
17,478
-4,641
-21% -$48.2K ﹤0.01% 2416
2022
Q2 		$749K Buy
+22,119
New +$195K ﹤0.01% 1561

Other funds holding CCCC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Mirae Asset Global Investments's CCCC Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its C4 Therapeutics (CCCC) stake by 2.8% in Q2 2026, selling an estimated $496 and leaving 4,945 shares worth $23.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1470.

Mirae Asset Global Investments first reported a position in CCCC in Q2 2022 and has held it in 12 quarters since. The position peaked at $749K in Q2 2022. 38 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Mirae Asset Global Investments held 4,945 shares of C4 Therapeutics worth $23.1K as of Q2 2026.
  • Mirae Asset Global Investments sold 145 C4 Therapeutics shares in Q2 2026, an estimated $496.
  • C4 Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1470 holding.
  • Mirae Asset Global Investments first reported a position in C4 Therapeutics in Q2 2022 and has held it in 12 quarters since.
  • Mirae Asset Global Investments's C4 Therapeutics position peaked at $749K in Q2 2022.
  • 38 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.